Flex-prin

Ibuprofen


Provision Medical Products
Human Otc Drug
NDC 69103-2525
Flex-prin also known as Ibuprofen is a human otc drug labeled by 'Provision Medical Products'. National Drug Code (NDC) number for Flex-prin is 69103-2525. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Flex-prin drug includes Ibuprofen - 200 mg/1 . The currest status of Flex-prin drug is Active.

Drug Information:

Drug NDC: 69103-2525
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Flex-prin
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Ibuprofen
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Provision Medical Products
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:IBUPROFEN - 200 mg/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 31 Mar, 2015
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 18 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA079129
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2024
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Provision Medical Products
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:310965
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0858704004080
UPC stands for Universal Product Code.
NUI:N0000000160
M0001335
N0000175722
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:WK2XYI10QM
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class MOA:Cyclooxygenase Inhibitors [MoA]
Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`.
Pharmacologic Class EPC:Nonsteroidal Anti-inflammatory Drug [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class CS:Anti-Inflammatory Agents, Non-Steroidal [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Anti-Inflammatory Agents
Non-Steroidal [CS]
Cyclooxygenase Inhibitors [MoA]
Nonsteroidal Anti-inflammatory Drug [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
69103-2525-5250 PACKET in 1 CARTON (69103-2525-5) / 2 TABLET in 1 PACKET05 Apr, 2015N/ANo
69103-2525-6100 PACKET in 1 CARTON (69103-2525-6) / 2 TABLET in 1 PACKET05 Apr, 2015N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Pain reliever/fever reducer

Product Elements:

Flex-prin ibuprofen croscarmellose sodium carnauba wax hypromelloses polyethylene glycol 400 stearic acid cellulose, microcrystalline povidone k30 starch, pregelatinized corn polysorbate 80 silicon dioxide titanium dioxide talc ibuprofen ibuprofen ibu200

Indications and Usage:

Uses: temporarily relieves minor aches and pains due to:•headache • minor pain of arthritis • the common cold • toothache • backache • menstrual cramps • muscular aches • temporarily reduces fever

Warnings:

Warnings: allergy alert: ibuprofen may cause a severe allergic reaction which may include: • hives • shock • facial swelling • asthma (wheezing) alcohol warning: if you consume 3 or more alcoholic drinks every day, ask your doctor whether you should take ibuprofen or other pain relievers/ fever reducers. ibuprofen may cause stomach bleeding. do not use: • if you have ever had an allergic reaction to any other pain reliever/fever reducer ask a doctor before use if you have: • stomach pain • problems or serious side eects from taking pain relievers or fever reducers ask a doctor or pharmacist before use if you are: • under a doctor's care for any serious condition • taking any other drug • taking any other product that contains ibuprofen, or any other pain reliever/fever reducer when using this product give with food or milk if stomach upset occurs. stop use and ask a doctor if: • an allergic reaction occurs. seek medical help right
away • pain gets worse or lasts more than 10 days • fever gets worse or lasts more than 3 days • stomach pain or upset gets worse or lasts • any new symptoms appear • redness or swelling is present in the painful area

Dosage and Administration:

Directions: • do not take more than directed. adults and children 12 years and older • take 1 tablet every 4 to 6 hours while symptoms • if pain or fever does not respond to 1 tablet, 2 tablets may be used. do not exceed 6 tablets in 24 hours, unless as directed by a doctor. • the smallest effective dose should be used. children under 12 year • ask a doctor.

Package Label Principal Display Panel:

Flex prin box


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.